Nxera Pharma

Nxera Pharma is a Japanese-headquartered biopharmaceutical company leveraging its proprietary structure-based drug discovery platform, NxWave™, to develop specialty medicines targeting unmet needs primarily in neurology/neuropsychiatry, metabolic diseases, immunology/inflammation, gastrointestinal disorders, and rare diseases. The company operates globally with commercial operations focused on Japan/APAC. It has over thirty active programs spanning from discovery to late clinical stages internally or via partnerships. Several products are already launched in Japan/APAC markets; lead assets include PIVLAZ for cerebral vasospasm post-subarachnoid hemorrhage and Quviviq for insomnia. Recent milestones include a Phase 3 trial start for NBI‑1117568 for schizophrenia by partner Neurocrine Biosciences.